Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®)
eye injections reduces the need for repeat bevacizumab eye injections in patients with
nonischemic central retina vein occlusion.